Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Published:2014-07 Issue:9940 Volume:384 Page:319-328
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Brose Marcia S,Nutting Christopher M,Jarzab Barbara,Elisei Rossella,Siena Salvatore,Bastholt Lars,de la Fouchardiere Christelle,Pacini Furio,Paschke Ralf,Shong Young Kee,Sherman Steven I,Smit Johannes W A,Chung John,Kappeler Christian,Peña Carol,Molnár István,Schlumberger Martin J

Publisher

Elsevier BV

Subject

General Medicine

Reference29 articles.

1. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer;Cooper;Thyroid,2009

2. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma;Shoup;J Am Coll Surg,2003

3. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy;Durante;J Clin Endocrinol Metab,2006

4. Definition and management of radioactive iodine-refractory differentiated thyroid cancer;Schlumberger;Lancet Diabetes Endocrinol,2014

5. Molecular pathogenesis and mechanisms of thyroid cancer;Xing;Nat Rev Cancer,2013

Cited by 1326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A versatile nanoplatform carrying cascade Pt nanozymes remodeling tumor microenvironment for amplified sonodynamic/chemo therapy of thyroid cancer;Biomaterials;2025-02

2. Brain Metastases in Differentiated Thyroid Cancer: Clinical Presentation, Diagnosis, and Management;Thyroid®;2024-09-04

3. Targeting the RAS upstream and downstream signaling pathway for cancer treatment;European Journal of Pharmacology;2024-09

4. Sorafenib-Associated Bilateral Osteonecrosis of the Femoral Head;American Journal of Therapeutics;2024-09

5. Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database;Heliyon;2024-09